Postoperative dynamic changes in matrix metalloproteinase levels in patients with coronary artery bypass graft procedure complications

Kardiologiya

Volumn 52, Issue 9, 2012, Pages 4-7

  Golovkin, A S ^a   Matveeva, V C ^a   Grigoriev, E V ^a   Bayrakova, Y V ^a   Shukevich, D L ^a   Velikanova, E A ^a   Barbarash, O L ^a  

^a RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

Author keywords

Coronary artery bypass surgery; Matrix metalloproteinase; Postoperative complications

Indexed keywords

MATRIX METALLOPROTEINASE;

ARTICLE; BLOOD; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; METABOLISM; METHODOLOGY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME;

CORONARY ARTERY BYPASS; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIAL ISCHEMIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL INSUFFICIENCY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS;

EID: 84873727812     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ragino J.I., Chemjavskij A.M., Volkov M. et al. Factors and mechanisms of development of coronary atherosclerosis. Novosibirsk: Nauka 2011; 168.
2. Baroncinl V., Nakao L.S., Ramos 5. et al. Assessment of MMP-9, T1MP-I, and COX-2 in normal tissue and in advanced symptomatic and asymptomatic carotid plaques. Thrombosis J 2011 ;9:6.
3. Zi Xiaohong, Mutasem Abuhamed, Yuan Yi et al. Correlation Between MMP-3, TIMP-3 Expression and Neuronal Apoptosis After Ischemia - Reperfusion Injury in Rates. Am J Immunol 2007;3:25-30. (Pubitemid 351181641)
4. Vincent J. Organ dysfunctions as an outcome measure: The SOFA Score. Sepsis 1997;1:53-54. (Pubitemid 127507598)
5. Bone R.C., Sibbald W. J., Sprung C. L. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1483.
6. Ferroni P., Basili S., Martini F. et al. Serum metalloproteinase-9 levels in patients with coronaryartery disease: novel marker of inflammation. J Investig Med 2003;5:295-300. (Pubitemid 37210891)
7. Yasmin, McEniery CM. Wallace S. et al. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness. Arterioscler Thromb Vase Biol 2005;25:372-378. (Pubitemid 40189160)
8. Matveyeva KG., Golovkin A.S., Grigoryev E V. Role of triggering receptor expressed on myeloid cells in the activation of innate immunity. General Reanimatology 2011;3:61-65.
9. Lindsay MM., Maxwell P., Dunn F.G. T1MP-1 A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension. Hypertension 2002;40:136-141. (Pubitemid 34840088)
10. Lee M.A., Palace J., Stabler G. et al. Seram gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999;122:191-197. (Pubitemid 29067202)
11. Cheng M., Hashmi S., Mao X. et al. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008;24:385-390. (Pubitemid 351877358)